Inclusion Criteria:  The patient volunteered to participate in the study and signed the Informed Consent Age ≥18 years old ≤70 Years old, male or female Expected survival ≥ 12 weeks Intravascular large B-cell lymphoma confirmed by cytology or histology according to WHO2016 criteria Never received any anti-tumor therapies. Adequate organ function and adequate bone marrow reserve  Exclusion Criteria:  Malignant tumors other than IVLBCL within 5 years prior to screening, except cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery Active HIV, HBV, HCV or treponema pallidum infection Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy Female subjects who have been pregnant or breastfeeding, or who plan to conceive during or within 1 year after treatment, or male subjects' partner plans to conceive within 1 year after their cell transfusion Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment